{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:47:02Z","timestamp":1789847222725,"version":"4.0.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.beha.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T02:25:46Z","timestamp":1559787946000},"page":"239-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.1016","volume":"32","author":[{"given":"Xochiquetzal U.","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah R.","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.beha.2019.06.004_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2019.06.004_bib2","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2019.06.004_bib3","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.06.004_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.beha.2019.06.004_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08852.x","article-title":"Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"155","author":"Wong","year":"2011","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.beha.2019.06.004_bib7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","article-title":"Cutaneous T-cell lymphoma","volume":"37","author":"Pulitzer","year":"2017","journal-title":"Clin Lab Med"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"117","key":"10.1016\/j.beha.2019.06.004_bib12","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cyto.b.20395","article-title":"CD158k\/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry","volume":"74","author":"Bahler","year":"2008","journal-title":"Cytom B Clin Cytom"},{"issue":"12","key":"10.1016\/j.beha.2019.06.004_bib14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides","volume":"148","author":"Cetinozman","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2015.06.001","article-title":"Evaluation, diagnosis, and staging of cutaneous lymphoma","volume":"33","author":"Olsen","year":"2015","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.beha.2019.06.004_bib17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Canc Immunol Res"},{"issue":"7","key":"10.1016\/j.beha.2019.06.004_bib18","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2019.06.004_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0889-8588(18)30052-2","article-title":"Epidemiology and clinical manifestations of cutaneous T-cell lymphoma","volume":"9","author":"Koh","year":"1995","journal-title":"Hematol Oncol Clin N Am"},{"issue":"20","key":"10.1016\/j.beha.2019.06.004_bib20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/jnci\/81.20.1560","article-title":"Mycosis fungoides in relation to environmental exposures and immune response: a case-control study","volume":"81","author":"Whittemore","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib21","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1182\/blood.V83.9.2580.2580","article-title":"T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28","volume":"83","author":"Nickoloff","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib22","first-page":"452","article-title":"Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides)","volume":"61","author":"Storz","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib23","first-page":"636","article-title":"Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"16","author":"Jarrousse","year":"2006","journal-title":"Eur J Dermatol : EJD"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074287","article-title":"Contribution of toll-like receptor 2 to the innate response against Staphylococcus aureus infection in mice","volume":"8","author":"Yimin","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1523-1747.ep12494184","article-title":"Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins","volume":"98","author":"Tokura","year":"1992","journal-title":"J Investig Dermatol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib27","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-07-2247","article-title":"Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome","volume":"101","author":"Herne","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI117697","article-title":"The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients","volume":"95","author":"Pancake","year":"1995","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib29","first-page":"667","article-title":"No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma","volume":"150","author":"Wood","year":"1997","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jaad.2005.10.015","article-title":"Primary cutaneous T-cell lymphoma occurring after organ transplantation","volume":"54","author":"Ravat","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/DAD.0b013e318164cf6e","article-title":"Mycosis fungoides after solid-organ transplantation: report of 2 new cases","volume":"30","author":"Rodriguez-Gil","year":"2008","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib32","first-page":"291","article-title":"Successfully treated Hodgkin's disease followed by mycosis fungoides: case report and review of the literature","volume":"39","author":"Kaufman","year":"1987","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0190-9622(93)70201-4","article-title":"Cutaneous T-cell lymphoma associated with HIV infection","volume":"29","author":"Burns","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2004.11.060","article-title":"Cutaneous malignancy and human immunodeficiency virus disease","volume":"54","author":"Wilkins","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","article-title":"Aggressive cutaneous T-cell lymphomas after TNFalpha blockade","volume":"51","author":"Adams","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2019.06.004_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17834","article-title":"Cutaneous lymphomas appearing under biologics: 44 cases from the French study group on cutaneous lymphomas and French pharmacovigilance database","author":"Dequidt","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1046\/j.1365-2133.2001.04496.x","article-title":"Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients","volume":"145","author":"Hodak","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/1523-1747.ep12363352","article-title":"HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma","volume":"107","author":"Jackow","year":"1996","journal-title":"J Investig Dermatol"},{"issue":"8","key":"10.1016\/j.beha.2019.06.004_bib39","first-page":"594","article-title":"Pathogenesis of mycosis fungoides","volume":"9","author":"Beyer","year":"2011","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft = J Ger Soc Dermatol : JDDG"},{"issue":"10","key":"10.1016\/j.beha.2019.06.004_bib40","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-08-4631","article-title":"Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death","volume":"69","author":"Klemke","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.24233","article-title":"Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.beha.2019.06.004_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood.V128.22.1826.1826","article-title":"First-in-Human, multicenter phase I study of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed\/refractory cutaneous T-cell lymphomas: preliminary safety, exploratory and clinical activity results","volume":"128","author":"Bagot","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2133.2002.04966.x","article-title":"Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides","volume":"147","author":"Mao","year":"2002","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.0022-202X.2004.22301.x","article-title":"Genomic aberrations and survival in cutaneous T cell lymphomas","volume":"122","author":"Fischer","year":"2004","journal-title":"J Investig Dermatol"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"21","key":"10.1016\/j.beha.2019.06.004_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V124.21.706.706","article-title":"Integrated genome sequencing reveals frequent loss of function alterations of ARID1A and other epigenetic modifiers in sezary syndrome","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib47","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.beha.2019.06.004_bib48","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood"},{"issue":"4 Suppl","key":"10.1016\/j.beha.2019.06.004_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/12034754030070S402","article-title":"Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2003","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"10.1016\/j.beha.2019.06.004_bib50","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.4049\/jimmunol.174.10.5968","article-title":"Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells","volume":"174","author":"Maeda","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib53","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.beha.2019.06.004_bib54","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib55","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2019.06.004_bib56","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib57","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib58","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib59","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.beha.2019.06.004_bib62","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","article-title":"Systematic review of combination therapies for mycosis fungoides","volume":"40","author":"Humme","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2019.06.004_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2019.06.004_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40257-018-0380-7","article-title":"Current status of HDAC inhibitors in cutaneous T-cell lymphoma","volume":"19","author":"Lopez","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"10.1016\/j.beha.2019.06.004_bib67","doi-asserted-by":"crossref","first-page":"39627","DOI":"10.18632\/oncotarget.17383","article-title":"Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sezary syndrome","volume":"8","author":"Izykowska","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLML.2010.n.014","article-title":"The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma","volume":"10","author":"Hymes","year":"2010","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.beha.2019.06.004_bib70","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"29","key":"10.1016\/j.beha.2019.06.004_bib73","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"32","key":"10.1016\/j.beha.2019.06.004_bib74","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2019.06.004_bib75","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib76","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib77","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.beha.2019.06.004_bib78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.beha.2019.06.004_bib79","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib80","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.beha.2019.06.004_bib81","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.06.004_bib82","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.06.004_bib83","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1385\/MO:19:2S:S27","article-title":"Alemtuzumab in T-cell malignancies","volume":"19 Suppl","author":"Dearden","year":"2002","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib84","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620716636541","article-title":"Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential","volume":"7","author":"Duvic","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"22","key":"10.1016\/j.beha.2019.06.004_bib86","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"16","key":"10.1016\/j.beha.2019.06.004_bib87","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"12","key":"10.1016\/j.beha.2019.06.004_bib88","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2019.06.004_bib89","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2019.06.004_bib90","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib91","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2019.06.004_bib92","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1749-6632.2001.tb03718.x","article-title":"Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival","volume":"941","author":"Russell-Jones","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beha.2019.06.004_bib93","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2019.06.004_bib94","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/cco.2018.10.03","article-title":"Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sezary syndrome: a concise review","volume":"8","author":"Johnson","year":"2019","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib96","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0889-8588(03)00114-X","article-title":"High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma","volume":"17","author":"Oyama","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French society of bone marrow transplantation and French study group on cutaneous lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib98","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.beha.2019.06.004_bib99","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2019.06.004_bib100","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.beha.2019.06.004_bib101","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-017-2245-x","article-title":"Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"106","author":"Atilla","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2019.06.004_bib102","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00277-018-3275-z","article-title":"Allogeneic hematopoietic stem cell transplantation in primary cutaneous T cell lymphoma","volume":"97","author":"Cudillo","year":"2018","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.beha.2019.06.004_bib103","first-page":"CD008908","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma","author":"Schlaak","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.beha.2019.06.004_bib104","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"Suppl 3","key":"10.1016\/j.beha.2019.06.004_bib105","first-page":"39","article-title":"Prognostic and predictive markers for the new immunotherapies","volume":"28","author":"Mahoney","year":"2014","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib106","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Canc"},{"issue":"7655","key":"10.1016\/j.beha.2019.06.004_bib107","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.beha.2019.06.004_bib108","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 3","key":"10.1016\/j.beha.2019.06.004_bib109","first-page":"15","article-title":"Prospects for targeting PD-1 and PD-L1 in various tumor types","volume":"28","author":"Kim","year":"2014","journal-title":"Oncology"},{"key":"10.1016\/j.beha.2019.06.004_bib110","first-page":"132","article-title":"Phase 1\/2 trial of durvalumab and lenalidomide in patients with cutaneous T cell lymphoma (CTCL): preliminary results of phase I results and correlative studies","author":"Querfeld","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2019.06.004_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/antib7010003","article-title":"Tumor-directed blockade of CD47 with bispecific antibodies induces adaptive antitumor immunity","volume":"7","author":"Dheilly","year":"2018","journal-title":"Antibodies"},{"issue":"4","key":"10.1016\/j.beha.2019.06.004_bib112","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"issue":"2","key":"10.1016\/j.beha.2019.06.004_bib113","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2019.06.004_bib114","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRPalpha axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.beha.2019.06.004_bib115","article-title":"A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies","volume":"34","author":"Ansell","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.06.004_bib116","first-page":"130","author":"Querfeld","year":"2017","journal-title":"Signal Blood"},{"key":"10.1016\/j.beha.2019.06.004_bib117","first-page":"132","article-title":"IPH4102; an anti-KIR3DL2 monoclonal antibody in refractory sezary syndrome: results from a multicenter phase 1 trial","author":"Bagot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.06.004_bib118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V130.Suppl_1.820.820","article-title":"Phase 1 study of the safety and efficacy of MRG-106, a synthetic inhibitor of microRNA-155, in CTCL patients","volume":"130","author":"Querfeld","year":"2017","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619300453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:40Z","timestamp":1761498340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619300453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1521692619300453"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.06.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and S\u00e9zary syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}